These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 15681411

  • 1. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 3. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
    Lapenta C, Santini SM, Proietti E, Rizza P, Logozzi M, Spada M, Parlato S, Fais S, Pitha PM, Belardelli F.
    Virology; 1999 Oct 10; 263(1):78-88. PubMed ID: 10544084
    [Abstract] [Full Text] [Related]

  • 4. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH, Bühler B, Steinberger P, Tschan MP, Barbas CF, Torbett BE.
    Gene Ther; 2006 Oct 10; 13(20):1480-92. PubMed ID: 16738691
    [Abstract] [Full Text] [Related]

  • 5. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice.
    Yoshida A, Tanaka R, Kodama A, Yamamoto N, Ansari AA, Tanaka Y.
    Clin Dev Immunol; 2005 Dec 10; 12(4):235-42. PubMed ID: 16584108
    [Abstract] [Full Text] [Related]

  • 6. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.
    Virology; 2005 Jul 20; 338(1):182-99. PubMed ID: 15935415
    [Abstract] [Full Text] [Related]

  • 7. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model.
    Roth MD, Whittaker KM, Choi R, Tashkin DP, Baldwin GC.
    J Leukoc Biol; 2005 Dec 20; 78(6):1198-203. PubMed ID: 16204638
    [Abstract] [Full Text] [Related]

  • 8. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes.
    Roth MD, Tashkin DP, Choi R, Jamieson BD, Zack JA, Baldwin GC.
    J Infect Dis; 2002 Mar 01; 185(5):701-5. PubMed ID: 11865430
    [Abstract] [Full Text] [Related]

  • 9. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.
    Antimicrob Agents Chemother; 2005 Aug 01; 49(8):3474-82. PubMed ID: 16048963
    [Abstract] [Full Text] [Related]

  • 10. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
    Antimicrob Agents Chemother; 2005 Nov 01; 49(11):4584-91. PubMed ID: 16251299
    [Abstract] [Full Text] [Related]

  • 11. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.
    Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP.
    Virology; 2004 Oct 10; 328(1):19-29. PubMed ID: 15380354
    [Abstract] [Full Text] [Related]

  • 12. Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1.
    Sato K, Nie C, Misawa N, Tanaka Y, Ito M, Koyanagi Y.
    Vaccine; 2010 May 26; 28 Suppl 2():B32-7. PubMed ID: 20510741
    [Abstract] [Full Text] [Related]

  • 13. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse.
    Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC.
    Life Sci; 2005 Aug 19; 77(14):1711-22. PubMed ID: 15964028
    [Abstract] [Full Text] [Related]

  • 14. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 15. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
    Lapenta C, Spada M, Santini SM, Racca S, Dorigatti F, Poli G, Belardelli F, Alfano M.
    Int Immunol; 2005 Apr 23; 17(4):469-75. PubMed ID: 15746245
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
    J Med Chem; 2006 Jul 13; 49(14):4140-52. PubMed ID: 16821774
    [Abstract] [Full Text] [Related]

  • 17. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 13; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 18. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY, He SY, Zhang ZJ, He LF, Chen XW, Teng T.
    AIDS Res Hum Retroviruses; 2011 Oct 13; 27(10):1111-5. PubMed ID: 21375388
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells.
    Choi HJ, Dinarello CA, Shapiro L.
    J Infect Dis; 2001 Sep 01; 184(5):560-8. PubMed ID: 11494162
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.
    Antiviral Res; 2009 Jul 01; 83(1):86-9. PubMed ID: 19501260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.